메뉴 건너뛰기




Volumn 3, Issue 5, 2002, Pages 625-628

Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy

Author keywords

AT1 antagonists; Irbesartan; Losartan; Type 2 diabetes

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ B1 RECEPTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL;

EID: 0036091699     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.625     Document Type: Article
Times cited : (5)

References (16)
  • 4
    • 0006073010 scopus 로고    scopus 로고
    • US Renal Data System: USRDS 1999 annual data report. Bethesda, Maryland, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
    • (1999) , pp. 25-38
  • 7
    • 0034700790 scopus 로고    scopus 로고
    • Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy
    • Heart Outcomes Prevention Evaluation Study Investigators
    • (2000) Lancet , vol.355 , pp. 253-259
  • 10
    • 0031801034 scopus 로고    scopus 로고
    • In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
    • (1998) J. Am. Soc. Nephrol , vol.9 , pp. 1213-1224
    • Abbate, M.1    Zoya, C.2    Corna, D.3
  • 15
    • 0030604561 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy
    • The Gisen Group
    • (1997) Lancet , vol.349 , pp. 1857-1863


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.